Bitcoin traded near $86,000 on October 5 following a rally that lifted its weekly close by about 2%. This movement came after a partial clearing of Binance spot sell orders between $85,000 and $85,500, a key resistance area. U.S. spot Bitcoin ETFs saw net inflows of $208.1 million for the week ending October 4, although this was down 87.7% from the previous week. Spot trading volume declined slightly by 2% to $5.9 billion. Profit-taking by long-term holders increased during September's price rise, with a larger share of Bitcoin's supply in profit. The True Market Mean price, indicating average investor cost, was $77,200, providing a support level below the current market price.
Bitcoin price action near $86,000 provides context for Pluang's cryptocurrency market data. For readers following digital assets, here is Pluang's market snapshot as of Oct 07, 2026 03:33 WIB: Among 50 major cryptocurrencies priced on Pluang, 12 rose and 37 fell today. Notable movers include EOS (EOS.IO) with a 1-day change of +8.13% at Rp12.649 and a typical hold time of 87 days; UNI (Uniswap) down 5.12% at Rp155.141 with 35% sell and 65% buy order activity; and BAT (Basic Attention Token) down 4.97% at Rp1.796 with 26% sell and 74% buy order activity.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
Evercore ISI raised its price target for Marvell Technology to $433 from $275, maintaining an Outperform rating. This follows Marvell's optimistic revenue projections, expecting $20 billion by fiscal 2028 and $70-$90 billion by fiscal 2031, driven by...
